Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Jul 14, 2023
Neuren and Acadia expand global partnership for trofinetide
Jun 30, 2023
Neuren completes enrolment in Phelan-McDermid Phase 2 trial
Jun 28, 2023
Neuren opens first site in US for Prader-Willi Phase 2 trial
Jun 14, 2023
Change of Director's Interest Notice
Jun 07, 2023
Neuren receives US$40m milestone payment
Jun 05, 2023
Neuren presenting at Jefferies Global Healthcare Conference
May 30, 2023
Results of Meeting
May 30, 2023
AGM Chair Address & CEO Presentation
Apr 28, 2023
Notice of Annual General Meeting/Proxy Form
Apr 28, 2023
Virtual AGM online guide
Previous
1
2
3
4
5
Next
